Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...

Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, ...

Repurposed Drug use for cancer is exploding around the world. And today, New Year’s Day 2025, even Artificial Intelligence is ...

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...